Granted Patent
B2
US 12,649,739 · App. 18/037,340 · Granted Jun 9, 2026
Imidazoquinoline compound having anti-inflammatory, antifugal, antiparasitic, and anticancer activity
Inventors:
David Michael Simpson (North Bethesda, MD); Reid Warren Von Borstel (Potomac, MD); Rolando Alejandro Garcia Garcia (Germantown, MD)
Assignee:
PHARMA CINQ, LLC
View Patent ↗
Loading inventors, assignments & file history…
Abstract
An imidazoquinoline compound having activity against inflammation, fungi, unicellular parasitic microorganisms, and cancer is described.
Claims (14)
1 . A compound selected from the group consisting of:
2-(3-Phenoxybenzyl)-1H-imidazo[4,5-c]quinoline
and pharmaceutically acceptable salts thereof.
2 . A method for treating a condition in a mammalian subject; the condition being selected from the group consisting of an inflammatory disease and a neoplastic disease; comprising administering to the subject an effective amount of the compound of claim 1 .
3 . The method of claim 2 , wherein the mammalian subject is a human subject.
4 . The method of claim 2 , wherein the condition is an inflammatory disease, wherein the inflammatory disease is an inflammatory skin condition.
5 . The method of claim 4 , wherein the inflammatory skin condition is selected from the group consisting of psoriasis, psoriatic dermatitis, eczema, atopic dermatitis, and impetigo.
6 . The method of claim 2 , wherein the condition is an inflammatory disease, wherein the inflammatory disease is a systemic autoimmune disorder.
7 . The method of claim 6 , wherein the systemic autoimmune disorder is selected from the group consisting of rheumatoid arthritis, systemic and discoid lupus erythematosis, psoriatic arthritis, vasculitis, Sjogrens syndrome, scleroderma, autoimmune hepatitis, and multiple sclerosis.
8 . The method of claim 2 , wherein the condition is a neoplastic disease, wherein the neoplastic disease is a hematologic cancer or a solid tumor.
9 . A composition comprising the compound of claim 1 and further comprising a pharmaceutically acceptable carrier.
10 . The method of claim 2 wherein the compound is administered topically to the subject.
11 . The method of claim 2 wherein the compound is administered systemically to the subject.
12 . The method of claim 11 , wherein the compound is administered orally, rectally, parenterally, or nasally.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 3, 2023
From: SIMPSON, DAVID MICHAEL; VON BORSTEL, REID WARREN; GARCIA GARCIA, ROLANDO ALEJANDRO
To: WELLSTAT THERAPEUTICS CORPORATION
Reel/Frame 065457/0284 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 25, 2023
From: WELLSTAT THERAPEUTICS CORPORATION
To: PHARMA CINQ, LLC
Reel/Frame 065347/0384 →
Continuity (2)
Provisional Application
63122999
· Dec 9, 2020
References Cited (179)
US 3541094A
· Lutz et al.
· 1970
[cited by applicant]
US 4213987A
· Fujii et al.
· 1980
[cited by applicant]
US 4323680A
· Nakagami et al.
· 1982
[cited by applicant]
US 4331667A
· Schneider
· 1982
[cited by applicant]
US 4689338A
· Gerster
· 1987
[cited by applicant]
US 4698348A
· Gerster
· 1987
[cited by applicant]
US 4940714A
· Takada
· 1990
[cited by examiner]
US 5114939A
· Dreikorn et al.
· 1992
[cited by applicant]
US 5278173A
· Davis
· 1994
[cited by applicant]
US 5294622A
· Dreikorn et al.
· 1994
[cited by applicant]
US 5389640A
· Gerster et al.
· 1995
[cited by applicant]
US 5770599A
· Gibson
· 1998
[cited by applicant]
US 6046206A
· Pamukcu et al.
· 2000
[cited by applicant]
US 7138413B1
· Schwartz et al.
· 2006
[cited by applicant]
US 7153865B2
· D'Amico
· 2006
[cited by applicant]
US 7176213B2
· Aranyi et al.
· 2007
[cited by applicant]
US 7365089B2
· Aranyi et al.
· 2008
[cited by applicant]
US 7419977B2
· Aranyi et al.
· 2008
[cited by applicant]
US 7470709B2
· Barsanti et al.
· 2008
[cited by applicant]
US 7572915B2
· Barker et al.
· 2009
[cited by applicant]
US 7875624B2
· Heise et al.
· 2011
[cited by applicant]
US 7928111B2
· Tachdjian et al.
· 2011
[cited by applicant]
US 8637532B2
· Sutton et al.
· 2014
[cited by applicant]
US 20050137399A1
· Cai et al.
· 2005
[cited by applicant]
US 20080213308A1
· Valiante et al.
· 2008
[cited by applicant]
US 20100120741A1
· Borchardt et al.
· 2010
[cited by applicant]
US 20120258975A1
· Yuan et al.
· 2012
[cited by applicant]
US 20180298000A1
· Simpson et al.
· 2018
[cited by applicant]
AU 2535384A
· 1984
[cited by applicant]
CN 1034204C
· 1997
[cited by applicant]
CN 1311678A
· 2001
[cited by applicant]
DE 3406992A1
· 1984
[cited by applicant]
EP 0145340A2
· 1985
[cited by applicant]
EP 0370704A2
· 1990
[cited by applicant]
EP 0520722A1
· 1992
[cited by applicant]
EP 0566226B1
· 1995
[cited by applicant]
EP 0326331B1
· 2002
[cited by applicant]
GB 1182507A
· 1970
[cited by applicant]
GB 1496371A
· 1977
[cited by applicant]
GB 2068732A
· 1981
[cited by applicant]
GB 2135887A
· 1984
[cited by applicant]
JP S4320294Y1
· 1968
[cited by applicant]
JP S53103484A
· 1978
[cited by applicant]
JP S542325A
· 1979
[cited by applicant]
JP S5576803A
· 1980
[cited by applicant]
JP H01246266A
· 1989
[cited by applicant]
JP 2008514548A
· 2008
[cited by applicant]
JP 2011026251A
· 2011
[cited by applicant]
KR 20110121019A
· 2011
[cited by applicant]
RU 2248975C2
· 2005
[cited by applicant]
SU 1111675A3
· 1984
[cited by applicant]
WO 1990000055A1
· 1990
[cited by applicant]
WO 1992015582A1
· 1992
[cited by applicant]
WO 1996009294A1
· 1996
[cited by applicant]
WO 1997048705A1
· 1997
[cited by applicant]
WO 1998022446A1
· 1998
[cited by applicant]
WO 2005033079A1
· 2005
[cited by applicant]
WO 2006034235A2
· 2006
[cited by applicant]
WO 2006071095A1
· 2006
[cited by applicant]
WO 2007056170A2
· 2007
[cited by applicant]
WO 2007075468A1
· 2007
[cited by applicant]
WO 2010074783A1
· 2010
[cited by applicant]
WO 2011060207A1
· 2011
[cited by applicant]
WO 2012079079A1
· 2012
[cited by applicant]
WO 2012149186A2
· 2012
[cited by applicant]
International Search Report issued in PCT/US2021/062565, dated Feb. 23, 2022.
[cited by applicant]
Gerster et al., “Synthesis and Structure-Activity-Relationships of 1H-Imidazo[4,5-c]quinolines That Induce Interferon Production,” Journal of Medicinal Chemistry, vol. 48, pp. 3481-3491; 99. 3482 (2005).
[cited by applicant]
PUBMED Compound Record for CID 14621819, “3H-Imidazo[4,5-c]quinoline, 2-(phenylmethyl),” U.S. National Library of Medicine, pp. 1-9, available at https://pubchem.ncbi.nlm.nih.gov/compound/14621819) (2007).
[cited by applicant]
Adams et al., “Differences between central and peripheral rat alpha-adrenoceptors revealed using binuclear ligands,” Eur. J. Pharmacol. 127: 27-35 (1986).
[cited by applicant]
Alford et al., “Temporal infiltration of leukocyte subsets into mouse skin inflamed with phorbol ester,”
[cited by applicant]
Cantón et al., “Minimum fungicidal concentrations of amphotericin B for bloodstream
[cited by applicant]
Cavier et al., “Recherche sur les aminoquinoleines. XIX: Activite amoebicide in vivo d'alkylamino-4 quinoleines a longues chaines,” Ann. Pharm. Fr. 36(3-4): 115-119 (1978). English Summary attached.
[cited by applicant]
Chen et al., “[alpha]1-Adrenoceptor and serotonin 5-HT1A receptor affinity of homobivalent 4-aminoquinoline compounds: An investigation of the effect of linker length,” Biochem. Pharmacol. 85(10): 1534-1541 (2013).
[cited by applicant]
CLSI.
[cited by applicant]
CLSI.
[cited by applicant]
Deshpande et al., “p-Toluenesulphonyl derivatives of N,N′-bis-(4-quinolino-4-quinaldino/4-quinazolino and 9-acridino) polymethylene diamines as hypoglycemic agents,” J. Indian Chem. Soc. 52: 746-749 (1975).
[cited by applicant]
Desvignes et al., “Recherche sur les aminoquinoleines. XVIII: Activite antibacterienne et antifongique in vitro d'alkylamino-4 quinoleines a longues chaines,” Ann. Pharm. Fr. 35(7-8): 239-247 (1977). English Summary att…
[cited by applicant]
Ferguson et al., “The mutagenic effects of diacridines and diquinolines in microbial systems,” Mutation Res. 232: 337-343 (1990).
[cited by applicant]
Firestone et al., “Lysosomotropic agents. 7.1. Broad-spectrum antifungal activity of lysosomotropic detergents,” J. Med. Chem. 30(8): 1519-1521 (1987).
[cited by applicant]
Firestone, “Lysosomotropic agents. 1. Synthesis and cytotaxic action of lysosomotropic detergents,” J. Med. Chem. 22(9): 1130-1133 (1979).
[cited by applicant]
Galanakis et al., “Synthesis and quantitative structure-activity relationship of a novel series of small conductance Ca2+-activated K+ channel blockers related to dequalinium,” J. Med. Chem. 39: 359-370 (1996).
[cited by applicant]
Han et al., “Dual-site binding of bivalent 4-aminopyridine- and 4-aminoquinoline-based AChE inhibitors: contribution of the hydrophobic alkylene tether to monomer and dimer affinities,” Bioorg. Med. Chem. 7: 2569-2575 (…
[cited by applicant]
Harrison et al., “Conditional lethality of the diprotic weak bases chloroquine and quinacrine against Cryptococcus neoformans,”
[cited by applicant]
Hocart et al., “4-Aminoquinolines active against chloroquine-resistant Plasmodium falciparum: Basis of antiparasite activity and quantitative structure-activity relationship analyses,” Antimicrobial Agents and Chemother…
[cited by applicant]
Ikeda et al., “Structure-activity relationship in the antitumor activity of 6-, 8- or 6,8-substituted 3-benzylamino-β-carboline derivatives.”
[cited by applicant]
Isham et al., “Voriconazole and Caspofungin Cidality Against Non-Albicans
[cited by applicant]
Kovalenko et al., “Synthesis and Anticancer Activity of 2-(Alkyl-, Alkaryl-, Aryl-, Hetaryl-)- [1,2,4]triazolo[1,5-c]quinazolines,” Sci. Pharm. 81(2): 359-391 (2013).
[cited by applicant]
Li, Ping-ling, “Synthesis and evaluation of novel dimeric acetylcholinesterase inhibitors.” Master Thesis, Hong Kong University of Science and Technology (1998). Available from Sel. Org. React. Database (SORD).
[cited by applicant]
McAfee et al., “Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic authopagy deficiency,” PNAS 109(21): 8253-8258 (2012).
[cited by applicant]
McFadyen et al., “Alkyl-linked diquinolines are monofunctional AT-selective DNA-intercalating agents,” FEBS Letters 228(2): 235-240 (1988).
[cited by applicant]
McMahon, Gerald, “VEGF receptor signaling in tumor angiogenesis,” The Oncologist 5(S1):3-10 (2000).
[cited by applicant]
Miller et al., “Cell killing by lysosomotropic detergents,” J. Cell. Biol. 97(6): 1841-1851 (1983).
[cited by applicant]
Nadanaciva et al., “A high content screening assay for identifying lysosomotropic compounds,” Toxicol. in Vitro 25(3): 715-723 (2011).
[cited by applicant]
Nishimura et al., “Phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery annd structure—activity relationships of a series of quinoline and quinoxaline derivatives,” J. Med. Ch…
[cited by applicant]
Pedersen et al., “Phosphoramides: XVI. Mixtures of phosphorous pentoxide, amine hydrochlorides and tertiary amines as reagents in the synthesis of quinolinamines,” Chemica Scripta 18(5): 240-241 (1981).
[cited by applicant]
Pinedo et al., “Translational research: the role of VEGF in tumor angiogenesis,” The Oncologist, 5(S1):1-2 (2000).
[cited by applicant]
Pivtoraiko et al., “Low-dose bafilomycin attenuates neuronal cell death associated with autophagy lysosome pathway dysfunction,” Journal of Neurochemistry 114(4): 1193-1204 (2010).
[cited by applicant]
Renault et al., “Aminoquinoleines secondaires a activite amoebicide potentielle: influence de la longueur et de la position de la chaine alkylaminee,” C.R. Acad. Sc. Paris, Serie D, 282(5): 509-511; Feb. 1976. English S…
[cited by applicant]
Renault et al., “Recherche sur les aminoquinoleines. I. Etude des diverses methodes de syntheses des amino-4 quinoleines secondaires et tertiares a chaines hydrocarbonees,” Chimica Therapeutica 66(5-6): 339-346 (1966). …
[cited by applicant]
Srikanta et al., “A sensitive high-throughput assay for evaluating host-pathogen interactions in Cryptococcus neoformans infection,”
[cited by applicant]
Sukhai et al., “Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors,” J. Clin. Investigation 123(1): 315-328 (2013).
[cited by applicant]
Swindell et al., “Genome-wide expression profiling of five mouse models identifies similarities and differences with human psoriasis,” PLoS One. 6(4):e18266 (2011).
[cited by applicant]
Tomai et al., “Immunomodulating and antiviral activities of the imidazoquinoline S-28463,” Antiviral Res. 28(3):253-264 (1995).
[cited by applicant]
Van der Fits et al., “Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis,”
[cited by applicant]
Yap et al., “4-Arylalkoxyquinazolines with antifungal activity,” Chapter 26, pp. 258-272 in “Synthesis and Chemistry of Agrochemicals V.” Baker et al., eds. (ACS 1998).
[cited by applicant]
Extended European Search Report issued in EP 14746786.4, dated Sep. 28, 2016.
[cited by applicant]
Examination Report issued in AU 2014212242, dated Dec. 13, 2016.
[cited by applicant]
CAS Registry No. 70137-87-0, STN Entry dated Nov. 16, 1984.
[cited by applicant]
CAS Registry No. 70137-92-7, STN Entry dated Nov. 16, 1984.
[cited by applicant]
CAS Registry No. 99011-37-7, STN Entry dated Nov. 9, 1985.
[cited by applicant]
CAS Registry No. 100818-54-0, STN Entry dated Mar. 15, 1986.
[cited by applicant]
CAS Registry No. 124532-49-6, STN Entry dated Jan. 5, 1990.
[cited by applicant]
CAS Registry No. 130338-83-9, STN Entry dated Nov. 9, 1990.
[cited by applicant]
CAS Registry No. 150450-55-8, STN Entry dated Oct. 7, 1993.
[cited by applicant]
CAS Registry No. 477846-50-7, STN Entry dated Dec. 31, 2002.
[cited by applicant]
CAS Registry No. 477861-85-1, STN Entry dated Dec. 31, 2002.
[cited by applicant]
CAS Registry No. 477861-86-2, STN Entry dated Dec. 31, 2002.
[cited by applicant]
CAS Registry No. 477861-94-2, STN Entry dated Dec. 31, 2002.
[cited by applicant]
CAS Registry No. 512803-46-2, STN Entry dated May 9, 2003.
[cited by applicant]
CAS Registry No. 512803-47-3, STN Entry dated May 9, 2003.
[cited by applicant]
CAS Registry No. 512803-48-4, STN Entry dated May 9, 2003.
[cited by applicant]
CAS Registry No. 853792-85-5, STN Entry dated Jul. 5, 2005.
[cited by applicant]
CAS Registry No. 896727-22-3, STN Entry dated Jul. 28, 2006.
[cited by applicant]
CAS Registry No. 896727-23-4, STN Entry dated Jul. 28, 2006.
[cited by applicant]
CAS Registry No. 896727-24-5, STN Entry dated Jul. 28, 2006.
[cited by applicant]
CAS Registry No. 896727-25-6, STN Entry dated Jul. 28, 2006.
[cited by applicant]
CAS Registry No. 896727-26-7, STN Entry dated Jul. 28, 2006.
[cited by applicant]
CAS Registry No. 896727-27-8, STN Entry dated Jul. 28, 2006.
[cited by applicant]
CAS Registry No. 896727-28-9, STN Entry dated Jul. 28, 2006.
[cited by applicant]
CAS Registry No. 926783-30-4, STN Entry dated Mar. 18, 2007.
[cited by applicant]
CAS Registry No. 929371-13-1, STN Entry dated Apr. 8, 2007.
[cited by applicant]
CAS Registry No. 929411-63-2, STN Entry dated Apr. 8, 2007.
[cited by applicant]
CAS Registry No. 929411-69-8, STN Entry dated Apr. 8, 2007.
[cited by applicant]
CAS Registry No. 1183483-77-3, STN Entry dated Sep. 13, 2009.
[cited by applicant]
CAS Registry No. 1219551-40-2, STN Entry dated Apr. 19, 2010.
[cited by applicant]
CAS Registry No. 1219574-88-5, STN Entry dated Apr. 19, 2010.
[cited by applicant]
CAS Registry No. 1223418-83-4, STN Entry dated May 14, 2010.
[cited by applicant]
CAS Registry No. 1262888-87-8, STN Entry dated Feb. 15, 2011.
[cited by applicant]
CAS Registry No. 1262888-93-6, STN Entry dated Feb. 15, 2011.
[cited by applicant]
CAS Registry No. 1262888-99-2, STN Entry dated Feb. 15, 2011.
[cited by applicant]
CAS Registry No. 1289188-18-6, STN Entry dated May 3, 2011.
[cited by applicant]
CAS Registry No. 1291543-40-2, STN Entry dated May 8, 2011.
[cited by applicant]
CAS Registry No. 1305730-10-2, STN Entry dated Jun. 5, 2011.
[cited by applicant]
CAS Registry No. 1306986-04-8, STN Entry dated Jun. 7, 2011.
[cited by applicant]
CAS Registry No. 1320982-96-4, STN Entry dated Aug. 21, 2011.
[cited by applicant]
CAS Registry No. 1327861-54-0, STN Entry dated Sep. 4, 2011.
[cited by applicant]
CAS Registry No. 1327861-60-8, STN Entry dated Sep. 4, 2011.
[cited by applicant]
CAS Registry No. 1327861-77-7, STN Entry dated Sep. 4, 2011.
[cited by applicant]
CAS Registry No. 1327947-30-7, STN Entry dated Sep. 4, 2011.
[cited by applicant]
CAS Registry No. 1328271-44-8, STN Entry dated Sep. 5, 2011.
[cited by applicant]
CAS Registry No. 1328292-16-5, STN Entry dated Sep. 5, 2011.
[cited by applicant]
CAS Registry No. 1328808-73-6, STN Entry dated Sep. 6, 2011.
[cited by applicant]
CAS Registry No. 1329224-28-3, STN Entry dated Sep. 7, 2011.
[cited by applicant]
CAS Registry No. 1329267-61-9, STN Entry dated Sep. 7, 2011.
[cited by applicant]
CAS Registry No. 1350730-84-5, STN Entry dated Dec. 13, 2011.
[cited by applicant]
RN384374-55-4, STN Registry, Jan. 19, 2002.
[cited by applicant]
RN1027641-33-3, STN Registry, Jun. 12, 2008.
[cited by applicant]
RN1292730-81-4, STN Registry, May 10, 2011.
[cited by applicant]
RN1303776-05-7, STN Registry, Jun. 1, 2011.
[cited by applicant]
RN1304938-90-6, STN Registry, Jun. 3, 2011.
[cited by applicant]
RN1305730-07-7, STN Registry, Jun. 5, 2011.
[cited by applicant]
RN1305730-17-9, STN Registry, Jun. 5, 2011.
[cited by applicant]
RN1305730-33-9, STN Registry, Jun. 5, 2011.
[cited by applicant]
STN Registry No. 1621343-19-8, 2014.
[cited by applicant]
STN Registry No. 1621343-21-2, 2014.
[cited by applicant]
Iwakura et al., “The IL-23/IL-17 axis in inflammation,”
[cited by applicant]
Wang, “Synthesis of 2H-indazole and benzimidazole derivatives based on radical reaction,”
[cited by applicant]